Bank of New York Mellon
RAPT

Bank of New York Mellon’s RAPT Therapeutics RAPT Stock Holding History

Bank of New York Mellon’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,338
Closed -$120K – 4243
2025
Q1 		$120K Buy
12,338
+1,070
+9% +$10.5K ﹤0.01% 3979
2024
Q4 		$142K Sell
11,268
-8
-0.1% -$102 ﹤0.01% 4004
2024
Q3 		$181K Sell
11,276
-3,048
-21% -$61.6K ﹤0.01% 3937
2024
Q2 		$349K Buy
14,324
+2,772
+24% +$128K ﹤0.01% 3748
2024
Q1 		$830K Sell
11,552
-1,176
-9% -$164K ﹤0.01% 3249
2023
Q4 		$2.53M Buy
12,728
+905
+8% +$112K ﹤0.01% 2713
2023
Q3 		$1.57M Buy
11,823
+2
+0% +$326 ﹤0.01% 2938
2023
Q2 		$1.77M Buy
11,821
+203
+2% +$31.6K ﹤0.01% 2914
2023
Q1 		$1.71M Buy
11,618
+1,315
+13% +$266K ﹤0.01% 2887
2022
Q4 		$1.63M Buy
10,303
+221
+2% +$35.4K ﹤0.01% 2951
2022
Q3 		$1.94M Buy
10,082
+1,086
+12% +$205K ﹤0.01% 2875
2022
Q2 		$1.31M Buy
8,996
+773
+9% +$103K ﹤0.01% 3068
2022
Q1 		$1.45M Sell
8,223
-23
-0.3% -$4.34K ﹤0.01% 3104
2021
Q4 		$2.42M Sell
8,246
-2,345
-22% -$627K ﹤0.01% 2881
2021
Q3 		$2.63M Buy
10,591
+1,705
+19% +$451K ﹤0.01% 2836
2021
Q2 		$2.26M Buy
8,886
+3,110
+54% +$581K ﹤0.01% 2907
2021
Q1 		$1.03M Sell
5,776
-71
-1% -$11.7K ﹤0.01% 3316
2020
Q4 		$925K Buy
5,847
+2,128
+57% +$463K ﹤0.01% 3290
2020
Q3 		$958K Buy
3,719
+32
+0.9% +$7.1K ﹤0.01% 3152
2020
Q2 		$855K Buy
+3,687
New +$570K ﹤0.01% 3195

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bank of New York Mellon's RAPT Position: Q2 2025 in Review

Bank of New York Mellon sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 12,338 shares — an estimated $120K sold.

Bank of New York Mellon first reported a position in RAPT in Q2 2020 and held it in 20 quarters. The position peaked at $2.63M in Q3 2021. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • Bank of New York Mellon reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 12,338 RAPT Therapeutics shares in Q2 2025, an estimated $120K.
  • Bank of New York Mellon first reported a position in RAPT Therapeutics in Q2 2020 and held it in 20 quarters.
  • Bank of New York Mellon's RAPT Therapeutics position peaked at $2.63M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.